NX5948, an oral Bruton’s tyrosine kinase (BTK) degrader, demonstrates robust BTK degradation in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies

Kim Linton

doi:10.1097/01.HS9.0000975912.59317.8d

NX5948, an oral Bruton’s tyrosine kinase (BTK) degrader, demonstrates robust BTK degradation in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies

Kim Linton

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

95 Downloads (Pure)

Original language	English
Journal	HemaSphere
DOIs	https://doi.org/10.1097/01.HS9.0000975912.59317.8d
Publication status	Published - 2023
Event	EHA2023 Hybrid Congress - Frankfurt, Germany Duration: 8 Jun 2023 → 15 Jun 2023

Access to Document

10.1097/01.HS9.0000975912.59317.8d

PB2296Final published version, 1.66 MB

Cite this

@article{3568ea90155f44ae9c7f7c27b8353048,

title = "NX5948, an oral Bruton{\textquoteright}s tyrosine kinase (BTK) degrader, demonstrates robust BTK degradation in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies",

author = "Kim Linton",

year = "2023",

doi = "10.1097/01.HS9.0000975912.59317.8d",

language = "English",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Lippincott Williams \& Wilkins",

note = "EHA2023 Hybrid Congress ; Conference date: 08-06-2023 Through 15-06-2023",

}

TY - JOUR

T1 - NX5948, an oral Bruton’s tyrosine kinase (BTK) degrader, demonstrates robust BTK degradation in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies

AU - Linton, Kim

PY - 2023

Y1 - 2023

U2 - 10.1097/01.HS9.0000975912.59317.8d

DO - 10.1097/01.HS9.0000975912.59317.8d

M3 - Meeting Abstract

SN - 2572-9241

JO - HemaSphere

JF - HemaSphere

T2 - EHA2023 Hybrid Congress

Y2 - 8 June 2023 through 15 June 2023

ER -